Assert-IQ vs SignalHF
AI Verdict
Choose Assert-IQ if…
Choose Assert-IQ if your primary objective is the long-term, continuous diagnosis and monitoring of patients with suspected or infrequent heart rhythm disorders. This insertable cardiac monitor is ideal for capturing elusive arrhythmias over an extended period, providing comprehensive data for definitive diagnosis and subsequent management.
View Assert-IQ →Choose SignalHF if…
Choose SignalHF if you need to proactively manage patients with existing cardiac implantable electronic devices (CIEDs) to prevent heart failure hospitalizations. This FDA-cleared AI algorithm excels at predicting acute heart failure events within 30 days, enabling timely intervention and personalized care plans based on real-time CIED data.
View SignalHF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
SignalHFSignalHF offers a unified platform that centralizes data from various cardiac implantable electronic devices and provides AI-driven alert management, significantly streamlining clinician workflows and reducing alert fatigue. While Assert-IQ features a patient mobile app and remote programmability, SignalHF's broader approach to managing complex multi-device data for healthcare teams presents a more impactful usability advantage.
Clinical Value
SignalHFSignalHF provides an FDA-cleared AI algorithm that predicts heart failure hospitalizations within 30 days, enabling proactive intervention and personalized care to potentially prevent adverse events. Assert-IQ offers long-term, continuous cardiac monitoring for arrhythmia detection. SignalHF's predictive capability for a critical outcome like hospitalization offers a distinct and potentially more impactful clinical benefit in preventing acute crises.
Pricing & Value
TieBoth Assert-IQ and SignalHF lack transparent pricing details, requiring direct contact with the respective companies for institutional or enterprise pricing. Neither tool offers a free trial. Without specific pricing information or published return on investment studies, it is not possible to definitively compare their value propositions.
Enterprise Readiness
SignalHFSignalHF, with its SaaS deployment, manufacturer-agnostic compatibility with various CIEDs, and features like automated billing workflows, demonstrates greater flexibility and ease of integration into diverse enterprise healthcare environments. Both tools are FDA-cleared and HIPAA compliant, but SignalHF's platform approach is more adaptable to a heterogeneous device landscape.
Innovation
SignalHFSignalHF's core innovation lies in its FDA-cleared, manufacturer-agnostic AI algorithm that proactively predicts heart failure hospitalizations by analyzing data from various CIEDs. While Assert-IQ incorporates advanced algorithms for long-term arrhythmia detection in an ICM, SignalHF's predictive AI for a specific clinical outcome represents a more significant and forward-looking application of AI in cardiovascular care.
Support & Docs
Assert-IQAbbott Medical, as a large and established medical device company, provides comprehensive support for Assert-IQ, including readily accessible manuals, guides for clinicians and patients, and dedicated technical support contact information. They also offer patient education support. While Implicity mentions instructions for use and brochures for SignalHF, the breadth and explicit accessibility of support channels appear more robust for Abbott.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Assert-IQ | SignalHF |
|---|---|---|
| Name | Assert-IQ | SignalHF |
| Company | Abbott Medical | Implicity |
| Description | The Assert-IQu2122 Insertable Cardiac Monitor (ICM) system provides long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders. | SignalHF by Implicity is an FDA-cleared AI algorithm that predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices, enabling early intervention and personalized care. |
| Tagline | Advanced, long-term insertable cardiac monitoring for comprehensive arrhythmia detection. | Revolutionizing Heart Failure Care with Predictive AI |
| Key Features | Long-term continuous cardiac monitoring (up to 6 years), Advanced arrhythmia detection algorithms, Bluetoothu00ae Low Energy data transmission, Secure cloud-based data platform, Remote monitoring capabilities, Proactive clinician alerts, Patient activator for symptom logging, Minimally invasive insertion | FDA-cleared AI algorithm for heart failure prediction, Predicts heart failure hospitalizations within 30 days, Manufacturer-agnostic compatibility with various CIEDs (pacemakers, ICDs, CRTs), Analyzes physiological data, demographics, lead measurements, episodes, and therapies, Generates automatic alerts for care teams based on risk scores, Enables early intervention and personalized care plans, Unified platform for centralizing cardiac implantable device data, AI-driven alert management to filter and highlight relevant events |
Videos
Demos, reviews, and walkthroughs featuring Assert-IQ and SignalHF.